About
Engage Bio has developed Tethosomes, a new class of non-viral DNA which finally unleashes potent, durable, redosable, and scalable genetic medicine.
In 2026 Engage was acquired by Eli Lilly.
In 2026 Engage was acquired by Eli Lilly.
Healthcare & Life Sciences
Looking for
Talent to hirePartners & collaboratorsFunding
Founders and key people
Highlights
Highlights coming soon
Notable work and milestones will show up here.
